Company: Highlight Therapeutics
Job title: Chief Executive Officer
Dr. Marisol Quintero has been CEO of Highlight Therapeutics, formerly known as Bioncotech, since 2013. Dr Quintero has significant experience in technology transfer and VC-funded life-sciences start-ups. She was previously Director of Innovation at the Spanish National Cancer Center (CNIO), Technology Transfer Manager at Fundación Botín where she supported the successful launch of the companies Life Length and Axontherapix. Marisol has a degree in Pharmacy from the University of Valencia, and obtained a PhD from her research studies on metabolic changes triggered by hypoxia at University College London; she also holds an Executive MBA from the Instituto de Empresa. Highlight Therapeutics is a private, clinical-stage company. Its lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.